Drug Information

Drug General Information
Drug ID
D0A1AQ
Former ID
DCL000631
Drug Name
Rosiglitazone + metformin
Drug Type
Small molecular drug
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Phase 3 [522062]
Company
GSK
Structure
Download
2D MOL

3D MOL
Formula
C18H18N2O3
Canonical SMILES
CC1=C(NC(=C1CCC(=O)O)C)C=C2C3=CC=CC=C3NC2=O
InChI
1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-
InChIKey
NHFDRBXTEDBWCZ-ZROIWOOFSA-N
CAS Number
CAS 122320-73-4
PubChem Compound ID
5329099
PubChem Substance ID
527809, 8034459, 11061326, 12015385, 14874233, 39301724, 53787898, 57287542, 57361293, 75555598, 81049299, 89388569, 99437172, 103175695, 113911629, 124757275, 125164079, 134338996, 134339167, 134964221, 135134779, 135182126, 135698723, 136340186, 136348238, 136367533, 136367774, 142063014, 143497361, 152234911, 152258241, 152344216, 160647077, 162011789, 162037617, 162202670, 163685934, 174561004, 177748855, 180386845, 185964372, 198939270, 204362248, 223366147, 223379505, 223705143, 226502638, 241376394, 242060022, 243278051
Target and Pathway
Target(s) Peroxisome proliferator activated receptor gamma Target Info Agonist [550963]
KEGG Pathway PPAR signaling pathway
AMPK signaling pathway
Osteoclast differentiation
Huntington's disease
Pathways in cancer
Transcriptional misregulation in cancer
Thyroid cancer
NetPath Pathway IL1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Leptin Signaling Pathway
PANTHER Pathway CCKR signaling map ST
Pathway Interaction Database Noncanonical Wnt signaling pathway
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Signaling events mediated by HDAC Class I
RXR and RAR heterodimerization with other nuclear receptor
Regulation of retinoblastoma protein
Reactome PPARA activates gene expression
Transcriptional regulation of white adipocyte differentiation
Nuclear Receptor transcription pathway
WikiPathways Wnt Signaling Pathway Netpath
Nuclear Receptors in Lipid Metabolism and Toxicity
Differentiation of white and brown adipocyte
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
Transcriptional Regulation of White Adipocyte Differentiation
Adipogenesis
SREBP signalling
Nuclear Receptors
References
Ref 522062ClinicalTrials.gov (NCT00499707) Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects. U.S. National Institutes of Health.
Ref 550963Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.